214 related articles for article (PubMed ID: 24204826)
1. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.
El Khatib M; Bozko P; Palagani V; Malek NP; Wilkens L; Plentz RR
PLoS One; 2013; 8(10):e77433. PubMed ID: 24204826
[TBL] [Abstract][Full Text] [Related]
2. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.
Frampton G; Coufal M; Li H; Ramirez J; DeMorrow S
Exp Cell Res; 2010 May; 316(9):1465-78. PubMed ID: 20347808
[TBL] [Abstract][Full Text] [Related]
3. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
4. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.
Aoki S; Mizuma M; Takahashi Y; Haji Y; Okada R; Abe T; Karasawa H; Tamai K; Okada T; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Katayose Y; Unno M
BMC Cancer; 2016 Nov; 16(1):854. PubMed ID: 27821106
[TBL] [Abstract][Full Text] [Related]
5. Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis.
Wutka A; Palagani V; Barat S; Chen X; El Khatib M; Götze J; Belahmer H; Zender S; Bozko P; Malek NP; Plentz RR
PLoS One; 2014; 9(4):e95605. PubMed ID: 24748170
[TBL] [Abstract][Full Text] [Related]
6. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
7. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
8. Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma.
Terada M; Horisawa K; Miura S; Takashima Y; Ohkawa Y; Sekiya S; Matsuda-Ito K; Suzuki A
Sci Rep; 2016 Oct; 6():34691. PubMed ID: 27698452
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of ATF3 repression of epithelial-mesenchymal transition and suppression of cell viability in cholangiocarcinoma via p53 signal pathway.
You Z; Xu J; Li B; Ye H; Chen L; Liu Y; Xiong X
J Cell Mol Med; 2019 Mar; 23(3):2184-2193. PubMed ID: 30648816
[TBL] [Abstract][Full Text] [Related]
10. Notch1 Drives the Formation and Proliferation of Intrahepatic Cholangiocarcinoma.
Guo J; Fu W; Xiang M; Zhang Y; Zhou K; Xu CR; Li L; Kuang D; Ye F
Curr Med Sci; 2019 Dec; 39(6):929-937. PubMed ID: 31845224
[TBL] [Abstract][Full Text] [Related]
11. NOV/CCN3 Promotes Cell Migration and Invasion in Intrahepatic Cholangiocarcinoma via miR-92a-3p.
Liang T; Shen L; Ji Y; Jia L; Dou Y; Guo L
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828265
[TBL] [Abstract][Full Text] [Related]
12. Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression.
Wu C; Zhang J; Cao X; Yang Q; Xia D
Med Sci Monit; 2016 Jul; 22():2685-90. PubMed ID: 27472451
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
14. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
Wang L; Dai G; Yang J; Wu W; Zhang W
Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
[TBL] [Abstract][Full Text] [Related]
15. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
[TBL] [Abstract][Full Text] [Related]
16. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
17. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
19. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.
Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR
PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026
[TBL] [Abstract][Full Text] [Related]
20. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Gu Y; Xiao L; Ming Y; Zheng Z; Li W
Int J Oncol; 2016 May; 48(5):1868-76. PubMed ID: 26935808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
